Skip to content
Menu

TD Cowen Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $115

Benzinga Newsdesk 1 day ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

TD Cowen analyst Nicholas Lorusso maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Buy and raises the price target from $100 to $115.

TD Cowen analyst Nicholas Lorusso maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Buy and raises the price target from $100 to $115.

Read at benzinga.com